Hostname: page-component-6766d58669-nqrmd Total loading time: 0 Render date: 2026-05-19T12:35:30.816Z Has data issue: false hasContentIssue false
  • English
  • Français

Rapidly progressing giant invasive prolactinoma

Published online by Cambridge University Press:  29 June 2012

R H Care ,
V S Sunkaraneni ,
J Theaker  and
P G Harries
R H Care*
Affiliation:
ENT, Christchurch Hospital, Addington, New Zealand
V S Sunkaraneni
Affiliation:
ENT, Royal Surrey County Hospital, Guildford, UK
J Theaker
Affiliation:
Department of Histopathology, Southampton University Hospitals Trust, UK
P G Harries
Affiliation:
Department of ENT, Southampton University Hospitals Trust, UK
*
Address for correspondence: Dr Rachel Care, Christchurch Hospital, 2 Riccarton Avenue, Addington 8011, New Zealand E-mail: rachelcare@doctors.net.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We report an extremely rare case of a giant invasive prolactinoma presenting as a nasopharyngeal tumour.

Method:

Case report and literature review regarding giant prolactinoma.

Results:

Giant prolactinoma is a rare form of prolactinoma which accounts for 0.5–4.4 per cent of all pituitary tumours. It is more common in men and generally presents with symptoms of endocrine disturbance or neurological deficit.

Conclusion:

To our knowledge, this is the first report of giant prolactinoma presenting with symptoms of sinusitis and nasopharyngeal tumour.

Keywords

NasopharynxProlactinomaSinusitisRadiologyDiagnosis

Information

Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 126 , Issue 8 , August 2012 , pp. 840 - 843
Copyright
Copyright © JLO (1984) Limited 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Gillam, MP, Molitch, ME, Lombardi, G, Colao, A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485–534 CrossRefGoogle ScholarPubMed
2 Murphy, FY, Vesely, DL, Jordan, RM, Flanigan, S, Kohler, PO. Giant invasive prolactinomas. Am J Med 1987;83:995–1002 CrossRefGoogle ScholarPubMed
3 Colao, A, Sarno, AD, Cappabianca, P, Briganti, F, Pivonello, R, Somma, CD et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148:325–31CrossRefGoogle ScholarPubMed
4 Minniti, G, Jaffrain-Rea, ML, Santoro, A, Esposito, V, Ferrante, L, Delfini, R et al. Giant prolactinomas presenting as skull base tumors. Surg Neurol 2002;57:99–103 CrossRefGoogle ScholarPubMed
5 Dafer, RM, Jay, WM. Headache and the eye. Curr Opin Ophthalmol 2009;20:520–4CrossRefGoogle ScholarPubMed
6 Ciccarelli, E, Camanni, F. Diagnosis and drug therapy of prolactinoma. Drugs 1996;51:954–65CrossRefGoogle ScholarPubMed
7 Cho, EH, Lee, SA, Chung, JY, Koh, EH, Cho, YH, Kim, JH et al. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009;24:874–8CrossRefGoogle ScholarPubMed
8 Kreutzer, J, Buslei, R, Wallaschofski, H, Hofmann, B, Nimsky, C, Fahlbusch, R et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 2008;158:11–18 CrossRefGoogle Scholar